U.S. Markets closed

AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer

·1 min read
  • AIM ImmunoTech Inc's (NYSE: AIM) subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission for Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.

  • Among other benefits, products with Orphan designation can enjoy up to ten years of protection from market competition from similar medicines with similar active components and indications.

  • Earlier, the Committee had recommended that Ampligen receive the designation for pancreatic cancer.

  • Two weeks ago, the Netherlands regulatory authority approved rintatolimod (Ampligen) treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Program.

  • In September last year, a statistically significant positive pancreatic cancer survival benefit was observed in the Ampligen arm compared to a historical control cohort seen in a multi-year EAP conducted at Erasmus University Medical Center in the Netherlands. 

  • Price Action: AIM stock gained 11.7% at $2.53 on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.